Related Experiment Video
Updated: Aug 8, 2026
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
Published on: October 19, 2014
Clinical significance of monoclonal proteins in chronic lymphocytic leukemia
Z P Bernstein1, J E Fitzpatrick, A O'Donnell
1Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263.
Insights
High-resolution electrophoresis detected monoclonal proteins in 32% of chronic lymphocytic leukemia (CLL) patients, correlating with shorter survival. This finding may indicate higher risk for disease progression in early stages.
Area of Science:
- Hematology
- Oncology
- Clinical Chemistry
Background:
- Chronic lymphocytic leukemia (CLL) is a common B-cell malignancy.
- Monoclonal proteins in serum are potential biomarkers in hematological disorders.
- Accurate detection methods are crucial for prognostic assessment in CLL.
Purpose of the Study:
- To evaluate the prevalence of serum monoclonal proteins in CLL patients.
- To assess the prognostic significance of monoclonal proteins in CLL.
- To compare detection rates using different electrophoretic techniques.
Main Methods:
- High-resolution agarose gel electrophoresis with immunofixation was performed on 111 CLL patients.
- Serum protein electrophoresis (SPEP) and immunoelectrophoresis (IEP) were used for comparison.
- Survival data was analyzed in relation to monoclonal protein presence.
Main Results:
- Monoclonal proteins were detected in 32% of CLL patients by high-resolution electrophoresis, versus 20% (IEP) and 4% (SPEP).
- The presence of monoclonal proteins was associated with significantly shorter median survival (63 vs. 103 months, p < 0.012), independent of clinical stage.
- Monoclonal proteins may indicate increased risk for progression in early Rai stages (0-II).
Conclusions:
- High-resolution electrophoresis is a sensitive method for detecting monoclonal proteins in CLL.
- Serum monoclonal proteins are a significant negative prognostic factor in CLL, irrespective of stage.
- Further research is needed to confirm the predictive value of monoclonal proteins for disease progression in early-stage CLL.
Abstract:
Serum monoclonal proteins were found in 36 of 111 (32%) chronic lymphocytic leukemia (CLL) patients studied using high-resolution agarose gel electrophoresis combined with immunofixation. In contrast, using immunoelectrophoresis (IEP) and serum protein electrophoresis (SPEP), monoclonal proteins were found in 20 and 4% of CLL patients, respectively. The presence of a monoclonal protein was associated with a median survival of 63 months compared to 103 months for individuals without a monoclonal spike (p < 0.012). This was independent of clinical stage. The data also suggests that the presence of a monoclonal protein may define a group of patients at greater risk for disease progression in the low and intermediate risk groups. (Rai stages, 0, I, II). Further follow-up will be required to determine if this is statistically significant.
More Related Videos
09:02Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
11:39Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking
Published on: October 23, 2019
Related Concept Videos
01:15Differentiation of Common Myeloid Progenitor Cells
01:27Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...